Ernexa Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $582.0K | $68.0K | $0 | — | $5.8M | $19.8M |
| Cost of Revenue | — | — | $96.0K | $236.0K | $0 | — | — | — |
| Gross Profit | — | — | $486.0K | $-168.0K | $0 | — | — | — |
| Gross Margin | — | — | 83.5% | -247.1% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | $2.0K | $26.0K |
| SG&A Expense | — | $5.2M | $13.1M | $14.6M | $16.8M | $14.7M | $8.1M | $13.2M |
| Operating Income | — | $-9.3M | $-15.7M | $-21.1M | $-33.2M | $-113.7M | $-7.2M | $-1.8M |
| Operating Margin | — | — | -2,693.1% | -31,080.9% | — | — | -125.0% | -8.9% |
| Interest Expense | — | $22.0K | $174.0K | $614.0K | $30.0K | — | $118.0K | $236.0K |
| Pretax Income | — | $-14.1M | $-44.5M | $-21.7M | $-24.5M | $-122.5M | $-7.3M | $-2.0M |
| Income Tax Expense | — | $-45.0K | $30.0K | $-3.0K | $45.0K | $64.0K | $0 | $27.0K |
| Net Income | — | $-14.1M | $-44.5M | $-21.7M | $-24.6M | $-122.5M | $-7.3M | $-2.0M |
| Net Margin | — | — | -7,652.7% | -31,864.7% | — | — | -125.7% | -10.3% |
| EPS (Basic) | — | $-2.24 | $-6.99 | $-0.58 | $-1.15 | $-8.09 | $-0.06 | $-0.10 |
| EPS (Diluted) | — | $-2.24 | $-6.99 | $-0.58 | $-1.15 | $-8.09 | $-0.06 | $-0.10 |
| Shares Outstanding (Basic) | 29.2M | 6.3M | 6.4M | 37.2M | 21.4M | 15.2M | 123.1M | 20.3M |
| Shares Outstanding (Diluted) | 29.2M | 6.3M | 6.4M | 37.2M | 21.4M | 15.2M | 123.1M | 20.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |